hey greenisgood, yes this spells out the market opportunity.
Bioshares has just released a special report in light of this takeover, points below:
1. They say that Advanced Biohealing?s revenues have grown from US$9 million in 2007 to US$147 million in 2010 which represents only 5% of the US$3 billion diabetic foot ulcer market in the US.
2. This deal confirms the high medical need in this growing and under-penetrated market.
3. VitroGro is one of only a handful of promising new products and is one which could potentially compete on price and efficacy or even carve out a role as a valuable adjunct therapy.
4. The Shire takeover of Advanced Biohealing sends a clear signal that wound healing technologies/products are now very appealing growth areas, this bodes well for TIS. Shire said they will use this wound healing platform to potentially acquire additional regenerative medicine assets.
TIS Price at posting:
50.0¢ Sentiment: LT Buy Disclosure: Held
